Janus Henderson Group PLC Has $59.29 Million Stock Holdings in CARGO Therapeutics, Inc. (NASDAQ:CRGX)

Janus Henderson Group PLC cut its position in shares of CARGO Therapeutics, Inc. (NASDAQ:CRGX) by 1.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,659,580 shares of the company’s stock after selling 43,151 shares during the period. Janus Henderson Group PLC owned 0.07% of CARGO Therapeutics worth $59,286,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. RTW Investments LP acquired a new position in shares of CARGO Therapeutics during the 4th quarter worth about $119,821,000. Perceptive Advisors LLC bought a new stake in shares of CARGO Therapeutics during the 4th quarter worth about $79,557,000. Price T Rowe Associates Inc. MD grew its stake in CARGO Therapeutics by 38.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,093,347 shares of the company’s stock valued at $69,044,000 after buying an additional 854,840 shares during the last quarter. Wellington Management Group LLP acquired a new position in CARGO Therapeutics in the 4th quarter valued at about $39,009,000. Finally, Vanguard Group Inc. grew its stake in CARGO Therapeutics by 179.5% in the 1st quarter. Vanguard Group Inc. now owns 1,116,293 shares of the company’s stock valued at $24,916,000 after buying an additional 716,868 shares during the last quarter. 93.16% of the stock is currently owned by institutional investors and hedge funds.

CARGO Therapeutics Price Performance

Shares of CRGX stock traded down $0.09 during trading hours on Tuesday, hitting $16.90. 123,651 shares of the company’s stock traded hands, compared to its average volume of 236,382. The stock’s 50 day simple moving average is $17.25 and its 200 day simple moving average is $20.66. CARGO Therapeutics, Inc. has a 12 month low of $13.14 and a 12 month high of $33.92.

CARGO Therapeutics (NASDAQ:CRGX) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.18. As a group, equities analysts expect that CARGO Therapeutics, Inc. will post -4.59 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. HC Wainwright assumed coverage on shares of CARGO Therapeutics in a research note on Monday, July 22nd. They issued a “buy” rating and a $33.00 price target on the stock. Piper Sandler started coverage on shares of CARGO Therapeutics in a research report on Thursday, June 27th. They set an “overweight” rating and a $37.00 target price on the stock. Truist Financial restated a “buy” rating and set a $32.00 target price (down previously from $34.00) on shares of CARGO Therapeutics in a research report on Thursday, May 16th. Finally, Chardan Capital began coverage on shares of CARGO Therapeutics in a research report on Monday, July 8th. They set a “buy” rating and a $28.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, CARGO Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $30.83.

Insider Transactions at CARGO Therapeutics

In other news, major shareholder Samsara Biocapital Gp, Llc acquired 294,000 shares of the firm’s stock in a transaction dated Thursday, May 30th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $4,998,000.00. Following the completion of the transaction, the insider now directly owns 4,415,689 shares in the company, valued at approximately $75,066,713. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.38% of the stock is currently owned by corporate insiders.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.